Marinomed Biotech AG (VIE:MARI)

Market Cap	25.43M
Revenue (ttm)	6.60M
Net Income (ttm)	-6.87M
Shares Out	1.78M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120
Average Volume	904
Open	14.30
Previous Close	14.30
Day's Range	14.30 - 14.30
52-Week Range	2.00 - 23.80
Beta	-0.09
RSI	50.87
Earnings Date	Apr 16, 2025

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 52
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI

Financial Performance

In 2023, Marinomed Biotech AG's revenue was 9.18 million, a decrease of -18.56% compared to the previous year's 11.28 million. Losses were -6.79 million, 6.21% more than in 2022.